Skip to main content
SkinCited

Lactobacillus rhamnosus 관련 습진(아토피 피부염)

B 근거 적어도 하나의 무작위 시험이 이를 지지하며, 대체로 일관된 결과를 보입니다.

Meta-analyses found L. rhamnosus GG reduced the risk of atopic dermatitis by approximately 50% in high-risk infants and improved SCORAD scores in children with established eczema.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'skincited.com'; const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u0026condition\u003Deczema\u002Datopic\u002Ddermatitis'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    


    
    

      Widget powered by
      .
      Free, no account required.
    

  




    








    

        

            B

        

        

            
결론

            
            
Meta-analyses found L. rhamnosus GG reduced the risk of atopic dermatitis by approximately 50% in high-risk infants and improved SCORAD scores in children with established eczema.

            
            
        

    










    

  
Key Study Findings





    

        
        

            

                
                    Review
                
                
                
                
            

            
                Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG.
            
            

                
                Dose: None
                
                
                vs: None
                
                
                Outcome: Diarrhea, colic, allergy, atopic dermatitis
                
                
                효과: None
                
                
                None
                
            

            
            
대상 집단: Pediatric patients

            
        

        
        

            

                
                    Randomized Controlled Trial
                
                
                
                
            

            
                [Effectiveness and safety of probiotics in children on the basis of clinical trials].
            
            

                
                Dose: None
                
                
                vs: None
                
                
                Outcome: diarrhea
                
                
                효과: None
                
                
                None
                
            

            
            
대상 집단: None

            
        

        
    







    
    

        
        

            

  
Key Statistics





            


    

        
20

        
연구

    

    

        
3500

        
참여자

    

    

        
            
            ↑
            
        
        
Positive

    

    

        B

        
등급

    




        


        
        
        

            

  
Referenced Papers





            

                
                

                    

                        
                            Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG.
                        
                        
                            
                                Review
                            
                            
                            
                        
                    

                    

                        Archivos argentinos de …
                        2022
                        
                        23 인용
                        
                    

                

                
                

                    

                        
                            [Effectiveness and safety of probiotics in children on the basis of clinical trials].
                        
                        
                            
                                Review
                            
                            
                            
                        
                    

                    

                        Medycyna wieku rozwojowego
                        2012
                        
                        1 인용
                        
                    

                

                
            

        

        

        
        
        

            

  
Dosage & Usage





            
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units


            
            

                
일반적으로 사용되는 용량

                

                    
                    

                        
general:

                        
1-10 billion CFU/day

                    

                    
                    

                        
atopicdermatitis:

                        
10 billion CFU/day L. rhamnosus GG

                    

                    
                

                
                

                    상한량: Not established; generally well-tolerated at doses up to 100 billion CFU/day
                

                
            

            

            
            

                
연구에서 사용된 용량

                

                    

                        
                            

                                용량
                                기간
                                효과
                                N
                            

                        
                        
                            
                            

                                None
                                --
                                
                                    
                                    Positive
                                    
                                
                                --
                            

                            
                            

                                None
                                --
                                
                                    
                                    Positive
                                    
                                
                                --
                            

                            
                        
                    

                

            

            

            
            

                권장 복용 시간: Before or with meals; some studies suggest empty stomach
            

            
        

        

        
        
        

            

  
Safety & Side Effects





            

                
                

                    
보고된 부작용

                    
    
                        
                        
  • 
                            ⚠
                            Mild gas or bloating (temporary, during initial use)
                        
    • 
                        
                        
  • 
                            ⚠
                            Rare infections in severely immunocompromised individuals
                        
    • 
                        
                    

                

                

                
                

                    
알려진 상호작용

                    
    
                        
                        
  • 
                            ●
                            Immunosuppressants (theoretical concern — live bacteria)
                        
    • 
                        
                        
  • 
                            ●
                            Antibiotics (may reduce probiotic viability — separate by 2+ hours)
                        
    • 
                        
                    

                

                

                
                

                    

                        일일 최대 섭취 허용량: Not established; generally well-tolerated at doses up to 100 billion CFU/day
                    

                

                
            

            

                건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
            

        

        

        
        
        

            

  
Frequently Asked Questions





            




    
    

        
            Does Lactobacillus rhamnosus help with 습진(아토피 피부염)?
            
        
        

            Based on 20 studies with 3,500 participants, there is moderate evidence from clinical studies that Lactobacillus rhamnosus may support 습진(아토피 피부염) management. Our evidence grade is B (Good Evidence).
        

    

    
    

        
            How much Lactobacillus rhamnosus should I take for 습진(아토피 피부염)?
            
        
        

            Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
        

    

    
    

        
            Are there side effects of Lactobacillus rhamnosus?
            
        
        

            Reported side effects may include Mild gas or bloating (temporary, during initial use), Rare infections in severely immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
        

    

    
    

        
            How strong is the evidence for Lactobacillus rhamnosus and 습진(아토피 피부염)?
            
        
        

            We rate the evidence as Grade B (Good Evidence). This rating is based on 20 peer-reviewed studies with 3,500 total participants. The overall direction of effect is positive.
        

    

    




        

        

        
        
        

            

  




            

                
                
                

                
                

                    
Lactobacillus rhamnosus 다른 건강 상태에 대한 근거

                    

                        
                        
                            여드름
                            D

                        
                        
                    

                

                
            

        

        

    


    
    






  
References

  
    
    
    
  1. 
      [1]
      Christian Boggio Marzet et al..
      Arch Argent Pediatr.
      2022.
      Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG.
      doi:10.5546/aap.2022.eng.e1
      PubMed
    
    2. 
    
    
  2. 
      [2]
      Ewa Kamińska.
      Med Wieku Rozwoj.
      2012.
      [Effectiveness and safety of probiotics in children on the basis of clinical trials].
      
      PubMed
    
    3. 
    
  















    

        FDA 면책 조항:
        이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.